Anthrax and plague vaccine-oral - AVANT

Drug Profile

Anthrax and plague vaccine-oral - AVANT

Latest Information Update: 03 May 2007

Price : $50

At a glance

  • Originator AVANT Immunotherapeutics
  • Developer DynPort Vaccine Company LLC
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anthrax; Yersinia infections

Most Recent Events

  • 03 May 2007 Discontinued - Preclinical for Yersinia infections in USA (PO)
  • 03 May 2007 Discontinued - Preclinical for Anthrax in USA (PO)
  • 23 Aug 2004 DynPort Vaccine Company LLC has been acquired by Computer Sciences Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top